So You Want to Do Omnichannel in Pharma
I spent about six years trying to make omnichannel actually work for a mid-size pharma company before I stopped trying to make it sound like something it isn't. People love to dress this up as a magic bullet. It is not. It is a fairly expensive way to make sure your message doesn't fall through the cracks when you are dealing with extremely regulated content, extremely cautious HCPs, and extremely fragmented channel ecosystems. At its core it means coordinating every touchpoint a healthcare professional has with your brand — reps, detail aids, email, web portals, conferences, peer-to-peer events, digital ads, KOL content — so that each one builds on the others instead of contradicting them or feeling like a cold call out of nowhere. A rep visits a doctor and within 48 hours that doctor gets a relevant email referencing something discussed. A digital ad follows up without being repetitive. The message stays consistent across channels but adapts to where the HCP actually is in their journey. The pharma side makes this harder than in any other industry because of compliance review cycles, medical legal review, and the fact that most channels require separate approvals even when the core message is identical. If you run a campaign across five channels and each one goes through MSL review independently, you are looking at a two to four week delay before anything launches. That is the baseline reality.
I remember a specific project where we were launching a new therapy for a chronic condition. We had CRM data suggesting that our target cardiologists consumed more peer-reviewed journal content than they did digital ads. So we designed a sequence where the initial touchpoint was a tailored article highlight sent via email, followed by a targeted LinkedIn message from the field team referencing that same content, then a rep visit with a physical copy of the study. The idea was that by the time the rep walked in, the doctor already had context. What actually happened is that the CRM attribution model couldn't properly tie the email opens to the rep visits. We ended up sending three emails to the same people while the reps had no visibility into who had engaged. It cost us about $120,000 in wasted media spend and two months of rep time that could have been better allocated. The workaround was relatively simple but painful to implement — we moved from a siloed CRM setup to a unified customer data platform that could feed engagement signals back to the sales force in near real-time. That migration alone took about 14 weeks and required IT, compliance, and medical to sign off on data sharing protocols. After that, our conversion rate from first touch to rep visit increased by roughly 23 percent over the next quarter. But here is what nobody puts in the brochures. Omnichannel in pharma is only as good as your data infrastructure. Most organizations I have worked with had decent marketing automation but absolutely no unified view of the HCP. Sales had their own data. Digital had theirs. Medical affairs had yet another system. Trying to stitch these together without a CDP or at minimum a well-configured marketing platform with proper identity resolution is where most programs stall out. I have seen teams attempt this with spreadsheets and shared drives. It did not scale past about 200 key accounts before it completely broke down. Another counter-intuitive thing I learned is that more channels is not better. There is a sweet spot somewhere between three and five touchpoints per campaign sequence where additional channels actually decrease effectiveness because the messages start overlapping in ways that feel intrusive rather than coordinated. We tested this empirically on a respiratory product launch. The five-channel approach showed a 31 percent higher awareness lift than the three-channel approach, but the actual prescription conversion was nearly identical. The extra two channels — a webinar invite and a direct mail piece — added about $45,000 in cost for essentially zero incremental revenue. We dropped those and reinvested the budget into deeper content for the remaining channels. Conversion improved by about 8 percent the next quarter.
The biggest bottleneck in my experience is always medical and regulatory review. You might have perfect orchestration across all your channels and then the oncology team holds up a piece of content for six weeks because they want to reword a single safety statement. This ripples across every channel that was supposed to use that content simultaneously. The workaround is to build in a content staging buffer of at least three weeks and to separate evergreen content from time-sensitive campaign material. Evergreen pieces can go through review once and be reused. Time-sensitive content should be scoped narrowly with faster review cycles. It is not a perfect system but it keeps things from falling apart when compliance hits the brakes. If you are just getting started with this, don't try to boil the ocean. Pick one product, one therapeutic area, and maybe three channels. Get the orchestration right there before you expand. I have seen teams launch across twelve channels simultaneously and end up with inconsistent messaging everywhere because no one had time to review each one properly. A focused pilot with solid measurement beats a sprawling half-assed rollout every time. The other thing to consider is whether omnichannel is actually the right move for your specific situation. If you are in a niche therapeutic area with fewer than 500 active prescribers, a high-touch rep-led approach with some digital support might outperform a multi-channel strategy. The overhead of setting up and maintaining omnichannel infrastructure is significant — anywhere from $200,000 to $800,000 annually depending on complexity and whether you build in-house or work with a vendor. For smaller indications, that money might be better spent on simply having more frequent and better-trained field interactions.
Get the Full Details
There are tools that claim to solve this out of the box. Veeva, Salesforce Health Cloud, Sievel — they all have omnichannel modules. I have used most of them. They are better than building from scratch but they are not plug-and-play. Expect six to nine months of configuration, data migration, and testing before you see anything resembling a working campaign. And you will need someone internally who understands both the technology and the compliance requirements. Hiring that person is usually the hardest part of the whole process. The measurement side is also where most programs quietly die. Attribution in pharma is notoriously difficult because you cannot directly tie a digital ad to a prescription. The best proxy metrics are HCP engagement scores, content consumption rates, and rep visit quality scores. You will also want to track message consistency across channels. I set up a simple audit process where a random sample of 10 percent of all touchpoints across a campaign were reviewed for message alignment and compliance accuracy. This caught about 15 percent of issues before they reached the field or the inbox. It added maybe two hours per week to the workflow but prevented what could have been a serious compliance incident on one occasion. The landscape keeps shifting with digital adoption accelerating post-2020 and HCPs consuming more content online than ever before. The fundamental challenge hasn't really changed though. It is still about delivering the right message at the right time through the right channel while staying compliant. Everything else is just complexity layered on top of that.
If your organization is serious about this, the first step is usually a data infrastructure assessment. Figure out what systems you have, what they can talk to, and what is missing. Then pick one campaign to treat as a proof of concept. Document everything. Measure honestly. Expand only when you have proof it works in your specific context rather than assuming it will work because it worked somewhere else.
